Immunic Announces Grant of Key European Patent Protecting Relevant Dosing Regimens for Vidofludimus Calcium

Core Insights - Immunic, Inc. has received a key European patent for vidofludimus calcium, which protects relevant dosing regimens across all indications, including multiple sclerosis [1] - The patent is expected to provide protection in Europe until 2038, with potential extensions through a Supplementary Protection Certificate (SPC) possibly extending exclusivity to 2043 [1] - The company has a multi-layered intellectual property strategy that includes various patents covering composition-of-matter, treatment methods, and dosing regimens, ensuring robust protection for vidofludimus calcium [1] Company Overview - Immunic, Inc. is a late-stage biotechnology company focused on developing novel oral therapies for neurologic and gastrointestinal diseases [1] - The lead asset, vidofludimus calcium (IMU-838), is currently in phase 3 clinical trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026 [1] - Vidofludimus calcium has shown therapeutic activity in previous clinical trials, demonstrating significant reductions in brain lesions and disability progression in multiple sclerosis patients [1] Intellectual Property Strategy - The newly granted European patent (EP3713554) covers all forms of vidofludimus, including salts and solvates, and is designed to be difficult to design around [1] - Existing patents in the United States provide protection for vidofludimus calcium until at least 2041, with additional pending applications that could extend protection into 2044 and 2045 [1] - The company is actively working to expand its patent portfolio to maximize long-term exclusivity following potential regulatory approval [1]